Role of endonuclease G in senescence-associated cell death of human endothelial cells by Micutkova, L. et al.
 Role of endonuclease G in senescence-associated cell 
death of human endothelial cells 
Running title: EndoG in HUVEC senescence 
 
 
Thomas Diener1, Michael Neuhaus1, Rafal Koziel1, Lucia Micutkova1, Pidder Jansen-
Dürr1  
 1Institute for Biomedical Aging Research, Austrian Academy of Sciences, 
Rennweg 10, A-6020 Innsbruck, Austria  
 
*Address correspondence to: Dr. Pidder Jansen-Dürr, Institute for Biomedical Aging 
Research, Rennweg 10, A-6020 Innsbruck, Austria, Phone: +43-512-583919-44, 
FAX: +43-512-583919-8, email: p.jansen-duerr@oeaw.ac.at 
 
Keywords: HUVEC;EndoG;Senescence;Apoptosis. 
 2 
Abstract 
Mitotic cells in culture show a limited replicative potential and after extended 
subculturing undergo a terminal growth arrest termed cellular senescence. When 
cells reach the senescent phenotype, this is accompanied by a significant change in 
the cellular phenotype and massive changes in gene expression, including the 
upregulation of secreted factors. In human fibroblasts, senescent cells also acquire 
resistance to apoptosis. In contrary, in human endothelial cells, both replicative and 
stress-induced premature senescence is accompanied by increased cell death; 
however mechanisms of cell death are poorly explored. In this communication, we 
addressed the role of endonuclease G (EndoG), a mitochondrial mediator of 
caspase-independent cell death, in senescence-associated cell death of human 
endothelial cells. Using immunofluorescence microscopy, we found, that EndoG is 
localized in the mitochondria in young cells, but relocalizes to the nucleus upon 
senescence. When EndoG gene expression was downregulated by lentiviral shRNA 
vectors, we found a significant reduction in the replicative life span and a 
corresponding increase in cell death. We also observed a slight shift in the cell death 
phenotype from necrosis to apoptosis. Together these observations suggest an 
important role of EndoG in the senescence program of human endothelial cells. 
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1. Introduction 
Human ageing is accompanied by a degeneration of various tissues, which loose part 
of their physiological functions. Tissue degeneration is often accompanied by the loss 
of specialized cell types. In some cases, this is due to an exhaustion of the cell 
division capacity, as is best documented for ageing of the immune system (for 
review, see (Effros, 1996)) and for part of the skin ageing program (for review, see 
(Campisi, 1998)). Programmed cell death (apoptosis) apparently plays an important 
role during ageing of various tissues in vivo (for review, see (Warner et al., 1997)), 
and mice with a genetic defect in stress-related apoptosis display a significantly 
extended lifespan (Migliaccio et al., 1999). Tissue damage caused by age-dependent 
apoptosis has been documented in experimental animals (Adams et al., 1996; 
Nicosia et al., 1995; Usami et al., 1997). It is assumed that apoptosis plays an 
important role in tissue homeostasis, and the failure of cells to exert the apoptotic 
program can also lead to disorders which accumulate during ageing. For example, it 
was suggested that decreased efficiency of apoptosis contributes to the alterations 
characteristic of intrinsic (chronologic ageing) and extrinsic (photoageing) skin ageing 
(Haake et al., 1998). Together, these results suggest that regulation of programmed 
cell death plays an important role for the ageing process in vivo; however, the role of 
apoptosis for ageing may differ between various tissues. 
Concerning human ageing, many questions about molecular mechanisms have been 
addressed using in vitro senescence models derived from normal human cells. The 
proliferative potential of human primary cells in culture is limited, and extended 
passaging of such cells leads to a state of terminal growth arrest, referred to as 
replicative senescence. While the erosion of telomeres, due to insufficient telomerase 
activity (for review, see (Shawi and Autexier, 2008)), has been recognized as a 
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primary cause of replicative cellular senescence, a variety of other events have been 
identified that trigger premature senescence. Most notably, oxidative stress was 
found to induce premature senescence in human fibroblasts (Chen and Ames, 1994; 
von Zglinicki et al., 1995), endothelial cells (Kurz et al., 2004; Unterluggauer et al., 
2003), and a variety of other cell types (reviewed in ref. (Colavitti and Finkel, 2005)). 
It was shown that senescent fibroblasts are resistant to apoptosis (Wang, 1995), and 
p53-dependent apoptotic pathways are specifically blocked in senescent fibroblasts. 
Stabilization of p53 in response to DNA damage is impaired in old fibroblasts, 
resulting in induction of necrosis (Seluanov et al., 2001). While these results suggest 
a specific impairment of proapoptotic signalling in senescent fibroblasts, we found 
that human endothelial cells undergo age-associated cell death during in vitro ageing 
(Hampel et al., 2004; Wagner et al., 2001) and this was confirmed for bovine 
endothelial cells in independent experiments (Zhang et al., 2002). 
Apoptotic cell death can be triggered by a wide variety of environmental stimuli and 
the apoptotic response of a given cell is modified by a plethora of cellular gene 
products. The current knowledge in this field can be briefly summarized as follows: 
Apoptosis triggered by cell death receptors (e.g. the Fas/Fas ligand system)  leads to 
the activation of a class of proteases, referred to as caspases, in particular caspase 8 
and 10, which activate effector caspases (e.g. caspases 3, 6 or 7) (Nicholson, 1999). 
Effector caspases then cleave key substrates and thereby cause nuclear 
fragmentation. In an alternative pathway, mitochondrial function is altered through a 
variety of signals, ultimately leading to the opening of the mitochondrial permeability 
transition pore (PTP). PTP opening is modulated, among others, by members of the 
Bcl-2 gene family (for review, see (Bernardi et al., 2001)). Subsequently, soluble 
factors are released from the mitochondria to trigger an apoptotic response. These 
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factors include cytochrome C which, in combination with Apaf-1 (Zou et al., 1997), 
leads to activation of caspase 9, which then activates effector caspases, such as 
caspase 3 (Bratton et al., 2001). Simultaneously, other proapoptotic proteins, such as 
Smac (DIABLO), apoptosis inducing factor (AIF), and endonuclease G, are released 
from the mitochondria (Li et al., 2001; Parrish et al., 2001). 
Endonuclease G is a member of the conserved DNA/RNA non-specific ββα-Me-finger 
nuclease family which is located exclusively in the mitochondrial intermembrane 
space (Cote and Ruiz-Carrillo, 1993; Schafer et al., 2004) for recent review, see 
(Varecha et al., 2007). It is translated as a ~33 kDa preprotein and cleaved upon 
translocation into the mitochondria to a ~28 kDa protein, forming an active 
homodimer nuclease. EndoG was first isolated from calf thymus and is highly specific 
for (dG)n.(dC)n tracts in DNA which was first thought to be important in mitochondrial 
replication (Cote et al., 1989). Homologues have been described in many model 
organisms such as C. elegans (Parrish et al., 2001), M. musculus (Li et al., 2001), S. 
cerevisiae (Buttner et al., 2007a). The catalysis of phosphodiesters is dependent on 
the conserved residues His143, Asn174, and Glu182 which are necessary for metal 
binding while Arg141 is important for substrate binding (Schafer et al., 2004). In 
mouse embryonic fibroblasts, EndoG is translocated into the nucleus upon apoptotic 
stimuli and cleaves DNA chromatin into nucleosomal fragments which is not 
dependent on caspases (Li et al., 2001). Extramitochondrial expression of active 
EndoG causes cell death in HeLa cells, while expression of EndoG, mutated in the 
active centre, does not (Schafer et al., 2004). Also in yeast, overexpression of the 
EndoG homolog (Nuc1p) leads to cell death (Buttner et al., 2007a).  
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2. Materials and methods 
2.1. Cell culture 
Endothelial cells of two different donors were isolated from human umbilical veins 
and maintained on gelatine covered plates in Endothelial Cell Medium (Cambrex 
BioScience) in 5% CO2 at 37°C as described in (Unterluggauer et al., 2003). Cells 
were passaged when 70-80% of confluence was reached. Population doublings 
(PDL) were estimated using the following equation: n= (log10 F−log10 I)/0.301 (with 
n=population doublings, F=number of cells at the end of one passage, I=number of 
cells that were seeded at the beginning of one passage). After roughly 20 population 
doublings, the cells reached growth arrest. The senescent status was verified by in 
situ staining for SA-β-galactosidase as described (Dimri et al., 1995).  
For production of lentiviral particles, HEK-293T cells [human embryonic kidney 293 
cells expressing the large T-antigen of SV40 (simian virus 40)] were maintained in 
DMEM (Dulbecco's modified Eagle's medium) containing 2 mM L-glutamine, 100 
units/ml penicillin, 0.1 mg/ml streptomycin and 10% (w/v) fetal bovine serum (heat-
inactivated). 
The research has been performed in accordance with the Declaration of Helsinki 
(2000) of the World Medical Association and has been approved by the Ethics 
Committee of the Innsbruck Medical University. Consent was obtained from each 
patient after full explanation of the purpose, nature and risk of all procedures. 
 
2.2. Lentiviral gene knockdown 
Production of lentiviral particles was carried out according to the manufacturer's 
protocol (Addgene) using the packaging plasmids pMD2.G and psPAX2 (both 
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purchased from Addgene) and the lentiviral vector pLKO.1, containing EndoG-
specific shRNA (small-hairpin RNA) and control (scrambled) shRNA, respectively 
(Open Biosystems). For lentiviral infection, early passage HUVEC were cultivated in 
six-well plates. Upon reaching ~70% confluence, culture medium, containing lentiviral 
particles to the amount of 2 MOI (multiplicity of infection), was added to the cells in 
presence of 8 μg/ml hexadimethrine bromide (Sigma–Aldrich), which increases the 
efficiency of viral infection. At 24 h after infection, medium was changed. Puromycin 
selection was initiated (500 ng/ml) 72 h post infection. 
2.3. Measurement of mitochondrial membrane potential 
The electric potential of the inner mitochondrial membrane was measured in situ 
using flow cytometry in intact cells stained with JC-1 fluorescent probe (Cossarizza, 
1993). 
HUVECs were detached, cell number counted and 100 000 cells used for analysis. 
Cells were resuspended in EGM containing 0.5 µg/ml JC-1. Positive control was 
treated additionally with 5 µM FCCP. Cells were incubated for 30 min at 37°C, 
washed once with PBS containing 1 mM pyruvate and 5 mM glucose and 
resuspended in 300 µl PBS. JC-1 fluorescence was measured using a flow cytometer 
(BD FACSCanto™ II) (excitation with an argon laser at 488 nm and emission 
wavelength of 530/590 nm).  
2.4. FACS analysis of cell death 
For detection of apoptosis, HUVECs were detached and incubated in a fluorochrome 
buffer containing 0.1% (v/v) Triton-X-100, 50 µg/ml propidium iodide, dissolved in 
ddH2O. Cells were incubated for 30 min at 4°C, then analysed in FACS (BD 
FACSCanto™ II)(Nicoletti et al., 1991). For necrosis quantification, HUVECs were 
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detached and resuspended in 300 µl buffer containing 10 mM Hepes, 140 mM 
sodium chloride, 2.5 mM CaCl2, pH 7.4. Shortly before FACS measurement 1µl 
propidium iodide (1 µg/µl) was added. Measurement was done with and without 
addition of PI. 
2.5. Immunofluorescence 
HUVEC were seeded on glass slides (diameter 13mm) in six-well-plates using 100 
000 early passage cells or 50 000 late passage cells. On the following day cells were 
washed and fixed in 4% paraformaldehyde in PBS for 20 min at RT. Glass slides 
were transferred into 24-wells and cells were permeabilized with 0.1% Triton-X-100 
and 0.1% sodium citrate diluted in PBS for 2 min on ice. Cells were washed with PBS 
and incubated in blocking buffer (1% BSA in PBS) for 20 min at RT. Afterwards, glass 
slides were incubated with 50 µl of a 1:50 diluted rabbit polyclonal EndoG antibody 
(Abcam, Cambridge, US) in blocking buffer. After 45 min of incubation time, slides 
were washed three times with PBS and blocked for further 5 min in the blocking 
solution. Anti-rabbit antibody conjugated with FITC was applied in the same manner 
for 30 min. At last, 7-AAD (1 µg/ml) was added to blocking buffer for 30 min. Glass 
slides were washed with PBS twice and embedded in 7 µl DABCO. Analysis followed 
in a confocal microscope (Zeiss Axiophot). 
2.6. Western Blot 
Cells were harvested and lysed for 30 min on ice in a lysis buffer containing 50 mM 
Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Na-deoxycholate, 
0.2 mM phenylmethylsulfonyl-fluoride, 1 mM NaF, 10 μg/ml aprotinin, 10 μg/ml 
leupeptin. The lysates were centrifuged at 20 000 g for 10 min at 4 °C. 30 µg of 
protein for each sample was separated on a 12.5% SDS–polyacrylamide gel. After 
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electrophoresis, the proteins were transferred to PVDF membranes by wet 
electroblotting in a buffer containing 25 mM Tris–HCl, 190 mM glycine, 0.5% SDS, 
10% methanol. Transfer was controlled by staining the membrane with Ponceau S. 
Membrane was blocked in 5% non-fat dried milk in TBS-T [20 mM Tris–HCl pH 7.6, 
137 mM NaCl, 0.1% Tween 20] for 1 h at RT. Incubation with the anti-EndoG 
antibody (Abcam, Cambridge, US) was performed for 1h at RT; the membrane was 
washed twice with TBS-T and incubated with an anti-rabbit antibody from Dako 
(Glastrup, Denmark) conjugated with horseradish peroxidase (HRP) for 30 min. 
Immunoreactive proteins were detected using an enhanced chemiluminescence 
system (Amersham Life Science, Braunschweig, Germany).  
2.7. Caspase activity assay 
The Apo-ONE Homogeneous Caspase-3/7 Assay Kit obtained from Promega was 
used according to the protocol. Briefly, 70 000 cells per 96-well were used in 70 µl 
volume; 100 x substrate and buffer were mixed and 70 µl of the mixture was added to 
the cells. Background measurement was carried out with empty medium without 
cells; normal measurement was performed in duplicates measured at different time 
points with multiple reads per well using a TECAN® fluorimeter. Standard deviation 
was calculated from different reads of two wells. Fluorescence was measured using 
485 nm excitation and 530 nm emission wavelength. 
2.8. Subcellular fractionation using Qiagen Qproteome® Cell compartment Kit 
5 x 106 of early passage and 3x 106 of late passage HUVEC NS5 were used. Cells 
were detached and washed with ice-cold PBS and centrifuged at 500 x g for 10 min 
at 4°C. The cell pellets were resuspended in 2 ml ice-cold PBS, transferred into 
microcentrifuge tubes and centrifuged again at 500 x g for 10 min at 4°C. The cell 
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pellets were resuspended in 1 ml ice-cold Extraction buffer CE1 by pipetting up and 
down. Solutions was incubated for 10 min in an end-over-end shaker at 4°C. The 
lysates were centrifuged at 1000 x g for 10 min at 4°C. The supernatants (fraction 1 / 
cytosolic proteins) were transferred into fresh microcentrifugation tubes. The pellets 
were resuspended with 1 ml CE2 buffer and incubated for 30 min in an end-over-end 
shaker. Suspension were centrifuged at 6000 x g for 10 min at 4°C. Supernatants 
(fraction 2 / membrane proteins) were transferred into fresh microcentrifugation 
tubes. 7µl Benzoate was mixed with 13 µl distilled H2O, added to each pellet and 
incubated for 15 min at room temperature. After incubation time 500 µl ice-cold 
Extraction buffer CE3 was added to the solutions, incubated for 10 min at 4°C on an 
end-over-end shaker. The mixtures were centrifuged at 6800 x g for 10 min at 4°C. 
Supernatant (fraction 3 / nuclear proteins) were transferred to fresh tubes and stored 
on ice.  
Different fractions were applied on a 10% SDS-polyacrylamide gel loading 15µl of 
fraction 1, 25µl of fraction 2 and 35µl of fraction 3 to load equal protein contents. To 
qualify the fractionation process, immunodetection was carried out in the same way 
as described in 2.6. using a corresponding antibody per fraction For cytosolic 
proteins M2PK (ScheBo, Germany), for membrane proteins anti-OxPhos Complex V 
subunit (Invitrogen, Austria) and for nuclear proteins p84 (Abcam, Cambridge, US) 
antibodies were used. 
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3. Results  
3.1. Senescence-associated relocalization of EndoG  
To address a potential role of EndoG and its subcellular relocalization in senescence-
associated cell death of HUVEC, young and senescent cells were stained with 
antibodies to EndoG. To reveal a potential nuclear localization of EndoG, cells were 
counterstained with the DNA-specific nuclear dye 7-AAD. In young HUVEC, cytosolic 
localization of EndoG was observed, consistent with its known localization in 
mitochondria in healthy unstressed cells (Fig.1, upper panel). When EndoG was 
stained in senescent cultures, about 20 – 30% of the cells displayed nuclear 
localization of EndoG. This was particularly evident in cells with an irregular nuclear 
shape, indicative of cells undergoing apoptosis (Fig.1, lower panel). To corroborate 
these findings, early and late passage HUVEC were fractionated in a cytosolic, 
membrane and nuclear part where in both membrane and nuclear fractions, the 
EndoG signal was visible. The fractions were also probed with antibodies staining 
marker proteins known to be in the cytosolic, membrane and nuclear fraction. When 
comparing the amount of EndoG in the membrane fraction, early and late passages 
look the same but when comparing the nuclear fraction, the signal was stronger in 
late passage HUVEC. These results suggest that mitochondrial EndoG translocates 
to the nucleus in senescence-associated endothelial cell apoptosis. 
3.2. Functional consequences of EndoG inactivation 
To further address the role of EndoG in senescence-associated cell death, lentiviral 
vectors were constructed, which are suitable to knock down EndoG which is 
expressed in both young and, to a lesser extent, in senescent HUVEC (Fig.2A). 
Starting with five different knock down constructs, transfected in U2OS and analysed 
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by Western blot and immunofluorescence (data not shown), the two most promising 
ones (sh32 and sh35) were used in this study. Early passage and late passage 
HUVEC of two different donors were infected with lentiviral vectors carrying two 
different EndoG specific shRNA sequences, for control, a scrambled virus carrying a 
nonspecific (scrambled) shRNA was used. The knockdown was followed by Western 
blot (Fig.2 B) suggesting that significant reduction of EndoG protein levels could be 
obtained. Functional consequences of EndoG knock down were subsequently 
monitored. We found that knocking down EndoG in both early passage and late 
passage cells led to a significant delay in cell proliferation (Fig.2). This was 
accompanied by an increase in the percentage of cells staining positive for 
senescence-associated ß-galactosidase (Fig.2), suggesting that depletion of EndoG 
from human endothelial cells induces premature senescence. In yeast, EndoG was 
shown to be essential for mitochondrial function (Buttner et al., 2007a). To address, 
whether EndoG affects mitochondrial function in human endothelial cells, 
mitochondrial membrane potential was determined by staining with JC-1, a dye, 
which is sensitive to changes in mitochondrial membrane potential (Fig.3A). To 
control the experiment, mitochondrial membrane potential in young HUVEC was also 
measured with and without addition of the uncoupling agent FCCP. As expected, 
mitochondrial membrane potential was reduced to background levels by FCCP 
treatment. Under the same conditions, we found that knocking down EndoG in two 
different HUVEC strains by two different shRNA vectors had no significant effect on 
mitochondrial membrane potential (data not shown). 
3.3. EndoG and endothelial cell death 
Since cellular senescence of human endothelial cells is associated with an increased 
rate of spontaneous apoptosis, the effect of EndoG depletion on the rate of apoptosis 
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was monitored. To quantitate the rate of apoptosis, cells were permeabilized and 
DNA stained with propidium iodide; the percentage of subG1 fragments was 
determined by flow cytometry, increased from 16 ± 3 % in control cells to 36 ± 4 % in 
EndoG-depleted cells (Fig.3B, and data not shown). This experiment revealed a 
significant increase in apoptotic cell death as a result of EndoG knockdown, 
suggesting that EndoG is required for optimal survival of human endothelial cells. 
Increased apoptotic cell death was also confirmed by a Caspase-3/7 activity assay 
(data not shown), Interestingly, the group of cells with 4N DNA content, which 
contains tetraploid cells in G1 phase (Wagner et al., 2001) was significantly reduced 
upon depletion of EndoG (Fig.3 B). This could reflect the general anti-proliferative 
effect of EndoG knockdown; alternatively, the absence of cells with a DNA content of 
4N may also reflect preferential killing of polyploid cells by EndoG knockdown, as 
described previously (Buttner et al. 2007b). More work will be required to address this 
point. 
As it was reported that EndoG controls the balance between apoptosis and necrotic 
cell death in yeast cells (Buttner et al., 2007a), we also addressed the question, 
whether necrotic cell death may be modulated by EndoG knockdown. To monitor 
EndoG-dependent effects on necrosis, living cells were stained with propidium iodide, 
the uptake of which is characteristic of necrotic, but not apoptotic cell death (Fig.3C). 
Senescent HUVEC contained about 2.5% of necrotic cells, and this amount was 
slightly reduced by depletion of EndoG. Together these results suggest that EndoG 
protects human endothelial cells from apoptosis and at the same time increases the 
amount of necrotic cell death. 
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4. Discussion  
We show here that Endonuclease G is localized in the mitochondria in young human 
endothelial cells and appears in the nucleus in senescent HUVEC cultures, 
suggesting that senescence-associated cell death in human cells involves EndoG. 
This is further supported by our observation that knocking down EndoG in human 
endothelial cells leads to premature senescence, irrespective of the passage number 
at infection. Surprisingly, EndoG knockdown had no significant effect on 
mitochondrial membrane potential, but led to a significant increase in apoptotic cell 
death. Finally, we observed a trend for a decrease in necrosis in cells depleted of 
EndoG.  
4.1. Role of endonuclease G in cell death and disease 
Although well described as a potent inducer of caspase-independent cell death in 
response to stress, the physiological role of endonuclease G in mammalian cells has 
not been fully established. A former study showing the necessity of EndoG in 
embryogenesis (Zhang et al., 2003) couldn’t be verified by later studies, where 
EndoG knockout mice showed no deficiency in apoptosis or had any other phenotype 
(David et al., 2006; Irvine et al., 2005). Recent data from yeast established a mode of 
action for the yeast homolog of EndoG, and suggested that EndoG can have both 
vital and lethal activity, depending on the functional status of the mitochondria. 
Moreover the available data in yeast suggest a shift from age-associated apoptosis to 
necrosis upon depletion of EndoG (Buttner et al., 2007a). Recently, an inhibitor of 
EndoG  (EndoGI) was found in the D. melanogaster gene cg4930 which consists of 2 
homologous domains, each of them able to bind one EndoG nuclease (Temme et al., 
2009). The crystal structure of the complex was resolved which supported the 2:1 
stoichiometry (Loll et al., 2009). The group proposed a life insurance function for 
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EndoGI for leakage of mitochondria by release of EndoGI from the nucleus and 
binding EndoG in the cytosol. No human homolog was found yet. Nuclear localization 
of EndoG has also been observed in a variety of age-associated pathologies. Thus, 
cerebral ischemia (Lee et al., 2005; Nielsen et al., 2009) and muscle atrophy 
(Leeuwenburgh et al., 2005; Marzetti et al., 2008) have been connected to a nuclear 
translocation of EndoG, resulting in apoptosis and degeneration.  
4.2. Endothelial cell senescence and cell death in vascular pathology 
For ageing of the vascular system, a tissue-damaging role of apoptosis is well 
established (Heinrich and Holz, 1998). Arteriosclerosis, a major age-related disease 
of humans, is accompanied by a degeneration of vascular endothelial cells and 
vascular smooth muscle cells due to programmed cell death. In this context, the 
activation of the cellular suicide pathway leading to apoptosis of the endothelial cells 
represents an initial step in the development of arteriosclerotic lesions (Bennett, 
1999). Increased incidence of apoptosis in vitro was also observed when vascular 
smooth muscle cells from human atherosclerotic plaques were grown in vitro and 
compared to control cells (Bennett et al., 1998). Whereas there is compelling 
evidence that cell death by apoptosis contributes to vascular damage under 
pathological conditions (e.g., arteriosclerosis), the role of apoptosis during normal 
vascular ageing remains to be established. Our finding that endothelial cells undergo 
ageassociated apoptosis during in vitro ageing (Wagner et al., 2001) may provide a 
good model system for further studies. Age-related apoptosis is believed to play an 
important role during tissue ageing (Adams et al., 1996; Nicosia et al., 1995; Usami 
et al., 1997), and in vitro senescence of HUVEC may provide a new model for age-
related apoptosis that could be useful for studying the role of intrinsic and extrinsic 
ageing in certain vascular pathologies, e.g., arteriosclerosis  (Bennett, 1999). 
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Whereas the role of cellular senescence in normal ageing is still controversial, 
cellular senescence has been widely used as a model system to study ageing of 
various human tissues. Experimental evidence suggests that the occurrence of cells 
with a senescence-like phenotype is not restricted to tissue culture experiments. 
Senescent cells have been described in mitotic tissue of ageing rodents 
(Krishnamurthy et al., 2004), non-human primates (Jeyapalan et al., 2007), as well as 
in human aged tissues, such as the skin (Dimri et al., 1995; Ressler et al., 2006), the 
vascular system (Vasile et al., 2001) and the kidney (Melk et al., 2004). The 
premature appearance of senescent cells in the vascular endothelium has been 
associated with the onset of age-associated cardiovascular diseases, such as 
arteriosclerosis (Minamino et al., 2002). In light of these findings, our current 
observation, by both immunofluorescence and biochemical fractionation studies, that 
EndoG localizes to the nucleus in senescent endothelial cells and its role in 
modulating cell death may be of relevance for vascular diseases; however, more 
work will be required to elucidate the precise role of EndoG in age-associated 
vascular pathology. 
 
 17 
Acknowledgements 
We thank Brigitte Jenewein for excellent technical assistance. This work was 
supported by an FP6 grant (MiMage) from the EU and by the Austrian Science Funds 
(FWF; NFNS93). 
 18 
Legends to Figures 
Fig.1: Immunodetection of endogenous EndoG in human umbilical vein endothelial 
cells (HUVEC)  
A. The upper row shows young cells at passage 7, the lower row senescent cells at 
passage 20. Anti-EndoG antibody was stained in green, nucleus was stained with 7-
AAD (red). Images were taken in the same microscope with identical settings.  
B. Fractionation analysis of early and late passage HUVEC, showing cytosolic (1), 
membrane (2) and nuclear fraction (3). For each fraction a marker protein antibody 
was probed. EndoG is visible in the membrane fraction together with the 
mitochondrial marker OxPhos Complex V subunit, as well as in the nuclear fraction 
colocalizing with p84. No EndoG was found in the cytosol colocalizing with M2-PK.   
 
Fig.2: Effects of EndoG knockdown on cell proliferation and senescence.  
Experiments were done with two different donors (HUVEC #1 in B, HUVEC #5 in C) 
at early (ep) and late (lp) passages.  
A. Extracts were prepared of HUVEC in early and late passage as indicated and 
probed for EndoG by Western blot.  
B. Western blot probed with anti-EndoG shows reduced levels in knockdown samples 
(sh32, sh35) for early passage HUVEC two weeks post infection compared to control 
(upper left). The percentage of cells staining positive for senescence-associated β-
Galactosidase (SA-β-Gal) and the effects of knockdown are shown (upper right). 
Population doublings (PDL) are indicated in HUVEC infected with scrambled RNA 
and with EndoG shRNA (lower panel).  
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C. Western blot probed with anti-EndoG shows reduced levels in knockdown 
samples (sh32, sh35) for late passage HUVEC two weeks post infection compared to 
control (upper left). The percentage of cells staining positive for senescence-
associated β-Galactosidase (SA-β-Gal) and the effects of knockdown are shown 
(upper right). Population doublings (PDL) are indicated in HUVEC infected with 
scrambled RNA and with EndoG shRNA (lower panel). 
 
Fig.3: Effects of EndoG knockdown on cell death 
A. The ratio between a number of cells with high mitochondrial membrane potential 
(∆Ψ) and the uncoupled state is shown. ∆Ψ has been determined in JC-1 stained 
cells using FACS. As a positive control serve early passage (ep) cells, as a negative 
control the cells pre-treated with FCCP. Two different donors (HUVEC #1 and #5) 
were analysed in late passage (lp).  
B. HUVEC in late passage were permeabilized and stained with propidium iodide. 
Flow cytometry was performed and the percentage of subG1 DNA fragments was 
determined, as a measure for apoptotic cell death. 
C. HUVEC in late passage, as indicated, were directly stained with propidium iodide. 
Flow cytometry was performed and the percentage of PI positive cells was 
determined, as a measure for necrotic cell death.  
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